A Phase 3 interventional study of Tafamidis in Transthyretin (TTR) Amyloid Cardiomyopathy, sponsored by Pfizer. Completed at 80 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-03.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 58 studies in Amyloid Neuropathies, Familial with a site in United States — 23 open to participants now, 26 under way, 4 of them phase 3. Amyloid Neuropathies, Familial · United States.
Among the 58 studies in Amyloid Neuropathies, Familial with a site in United States, this one is the 2nd largest by enrollment of the 38 interventional ones that give a count, is one of 2 that started in 2016, is one of 14 in phase 3, and was the 12th registered.
188 studies on the registry are indexed under Amyloid Neuropathies, Familial; 94 are open to participants now.
Browse Amyloid Neuropathies, Familial studies →23 of the 58 studies in Amyloid Neuropathies, Familial with a site in United States are open now. Recruiting first, the newest first:
Brigham and Women's Hospital · Sites in United States
Ages 18+
Eidos Therapeutics, a BridgeBio company · Sites in United States
Ages 18–80
Mayo Clinic · Sites in United States
Ages 18+
University of Texas Southwestern Medical Center · Sites in United States
Ages 30–80
University of Minnesota · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 69 Amyloid Neuropathies, Familial studies recruiting now, 53 (77%) set no upper age limit and 1 (1%) stops at 75 or younger; 7 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
58 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 7 · Phase 3 17 · Phase 4 6
First in 2006; this study’s year is marked. 2 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,733 is above the median of 54 across 90 interventional studies indexed under Amyloid Neuropathies, Familial.
Median enrollment 53 across the 38 interventional studies, 125 across the 20 observational. Of the 29 that completed or were terminated, 17 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 58 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Pfizer has 9 studies filed under Amyloid Neuropathies, Familial — fewer than ten, so there is no comparison to draw.
11 of the studies in Amyloid Neuropathies, Familial with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05619302Phase 3Brigham and Women's HospitalMolecular Imaging of Myocardial Fibrosis in Cardiac Amyloidosis | 2026-12-31 |
| NCT07560306Phase 3Brigham and Women's Hospital[64Cu]FBP8 PET for Early Detection of Intracardiac Thrombus in Amyloid Cardiomyopathy | 2027-03-30 |
| NCT07196839University of Texas Southwestern Medical CenterDetermining the Association of TTR Stabilizing Therapy With Circulating TTR Amyloid Aggregates Over Time in Patients With ATTR-CM: Longitudinal Biomarker Study | 2026-12 |
| NCT07583823University of MinnesotaElevated Rate Pacing of Cardiac Amyloidosis | 2026-12-04 |
| NCT07062848Yale UniversityAn Observational Study Using Artificial Intelligence (AI) Algorithms on Electrocardiography (ECG), Point-of-care Ultrasound (POCUS), and Transthoracic Echocardiophy (TTE) to Estimate the Under-diagnosis of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Across a Diverse Range of US Health Systems. | 2027-01 |
Add all 11 to your calendar (.ics) → With an account.
Among the 58 studies in Amyloid Neuropathies, Familial with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Open label study to evaluate tafamidis for the treatment of transthyretin cardiomyopathy
Global Phase 3, open label long term extension safety study designed to obtain additional safety data for tafamidis meglumine 20 mg and 80 mg (or tafamidis 61 mg where available), and to continue to provide enrolled subjects with tafamidis for up to 60 months, or until subject has access to tafamidis for ATTR CM via prescription, whichever occurs first.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Cohort A: Completion of 30 months of study treatment on Pfizer Protocol B3461028
Cohort B: Patients in specific countries diagnosed with ATTR-CM who did not previously participate in Pfizer Study B3461028
Exclusion Criteria:
-Liver and/or heart transplant, or implanted cardiac mechanical assist device
Active treatment - 61 mg or if not available, tafamidis meglumine 80 mg
Drug: Tafamidis
Soft gel capsules administered once a day for 60 months
Time to All-Cause Mortality: Cohort A
Time to all-cause mortality was calculated from first dose of randomized treatment in parent study (B3461028) to all-cause mortality events. All-cause mortality events included deaths, heart transplants and cardiac mechanical assist devices implantation treated as death. Treated participants from the parent study who discontinued prior to the start of this study were also included in this analysis as planned. Data from participants who dropped out for a liver-only transplantation were handled in the same manner as the data from all other censored participants. Censored participants were participants who completed study or discontinued from the study (including discontinued by sponsor or participants withdrew, or discontinued due to Adverse event (AE), or alive at the time of analysis. Kaplan Meier method was used for analysis. Therefore, this analysis was based on the pooled dose groups, as per the statistical analysis plan (SAP).
Time frame: From first dose of randomized treatment in parent study (B3461028) up to 28 days post last dose of study treatment in current extension study (B3461045), [approximately up to 91 months]
Number of Participants With All-Cause Mortality Events: Cohort B
All-cause mortality included all participants who had discontinue for transplantation (i.e. heart transplantation and combined heart and liver transplantation) or for implantation of a cardiac mechanical assist device, were handled in the same manner as death. Data from participants who dropped out for a liver-only transplantation were handled in the same manner as the data from all other censored participants. Censored participants were participants who completed study or discontinued from the study (including discontinued by sponsor or participants withdrew, or discontinued due to AE), or alive at the time of analysis. Kaplan Meier method was used for analysis.
Time frame: B3461045: From first dose of treatment up to 28 days post last dose of study treatment (approximately up to 61 months)
Number of Participants With Treatment-Emergent Adverse Events (AEs)
An AE was any untoward medical occurrence in a participant who received investigational product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment or worsened during the treatment period relative to the pretreatment state. AEs included both SAEs and all Non-SAEs. A serious adverse event (SAE) was any untoward medical occurrence at any dose that: resulted in death; was life-threatening (immediate risk of death); required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/ incapacity; resulted in congenital anomaly/birth defect; considered an important medical event.
Time frame: B3461045: From first dose of treatment up to 28 days post last dose of study treatment (approximately up to 61 months)
Time to Cardiovascular-Related Mortality Events: Cohort A
Time to cardiovascular-related mortality was calculated from first dose of randomized treatment in B3461028 . Participants who discontinued for transplantation (that is heart transplantation and combined heart and liver transplantation) or for implantation of cardiac mechanical assist device were treated as a death. Treated participants from the parent study who discontinued prior to the start of this study were also included in this analysis as planned. Kaplan-Meier method was used. Therefore, this analysis was based on the pooled dose groups, as per the SAP.
Time frame: From first dose of randomized treatment in parent study (B3461028) up to 28 days post last dose of study treatment in current extension study (B3461045), [approximately up to 91 months]
Number of Participants With Cardiovascular Related Mortality Events: Cohort B
Deaths adjudicated as cardiovascular-related and indeterminate were reported. Cardiovascular-related mortality events included deaths, heart transplants and cardiac mechanical assist devices implantation treated as death. Cardiovascular relatedness was based on clinical judgement.
Time frame: B3461045: From first dose of treatment up to 28 days post last dose of study treatment (approximately up to 61 months)
Mean Annualized Rate of All Cause Hospitalizations
Mean annual rate of all cause hospitalization was calculated for each participant as the participant's number of all cause hospitalizations divided by this participant's duration on study in years. Hospitalization was defined as any initial admission (even less than 24 hours) in a hospital or equivalent healthcare facility or any prolongation of an existing admission. Only all cause hospitalizations where the participant was admitted to a hospital during the current extension study were included in this analysis. Any hospitalizations prior to randomization date were not included.
Time frame: B3461045: From first dose of treatment up to 28 days post last dose of study treatment (approximately up to 61 months)
Mean Annualized Rate of Cardiovascular (CV)-Related Hospitalizations
Mean annual rate of CV related hospitalization was calculated for each participant as the participant's number of CV related hospitalizations divided by this participant's duration on study in years. CV-related hospitalizations included hospitalizations due to heart failure, arrhythmia, myocardial infarction, stroke, and other cardiovascular-related events. Hospitalization was defined as any initial admission (even less than 24 hours) in a hospital or equivalent healthcare facility or any prolongation of an existing admission. Admission also included transfer within the hospital to an acute/intensive care unit (example: from the psychiatric wing to a medical floor, medical floor to a coronary care unit, or neurological floor to a tuberculosis unit).
Time frame: B3461045: From first dose of treatment up to 28 days post last dose of study treatment (approximately up to 61 months)
Change From Baseline in Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Scores at Months 12, 30, 42, 60 and 90: Cohort A
KCCQ: 23-item, self-administered questionnaire that assesses health status and health-related quality of life in participants with heart failure. KCCQ quantifies 8 domains: physical limitations, symptom stability, symptom frequency, symptom burden, total symptom (mean of symptom frequency and symptom burden), self-efficacy, quality of life and social limitations). Scores were generated for each domain and scaled from 0 (worst) to 100 (best possible status). KCCQ-clinical summary score was calculated as mean of the following domains- physical limitation and total symptoms and transformed to a single score which ranged from 0 (worst) -100 (best possible status), higher scores = better health status. Data for change from baseline was reported as least square (LS) mean.
Time frame: B3461028: Baseline (Day 1, pre-dose), Months 12, 30; B3461045: Months 42, 60 and 90 (time points were relative to Day 1 from B3461028; 42, 60 and 90 Months were 12, 30 and 60 Months of B3461045)
Change From Baseline in KCCQ Overall Score at Months 12, 30, 42, 60, 90: Cohort A
KCCQ: 23-item, self-administered questionnaire that assesses health status and health-related quality of life in participants with heart failure. KCCQ quantifies 8 domains: physical limitations, symptom stability, symptom frequency, symptom burden, total symptom (mean of symptom frequency and symptom burden), self-efficacy, quality of life and social limitations). Scores were generated for each domain and scaled from 0 (worst) to 100 (best possible status). KCCQ-overall score was calculated as mean of the following domains- physical limitation, total symptoms (average of symptom frequency \& symptom burden), quality of life, social limitation and transformed to a single score which ranged from 0 (worst) -100 (best possible status), higher scores = better health status. Data for change from baseline was reported as LS mean.
Time frame: B3461028: Baseline (Day 1, pre-dose), Months 12, 30; B3461045: Months 42, 60 and 90 (time points were relative to Day 1 from B3461028; 42, 60 and 90 Months were 12, 30 and 60 Months of B3461045)
Change From Baseline in KCCQ Total Symptom Score at Months 12, 30, 42, 60 and 90: Cohort A
KCCQ: 23-item, self-administered questionnaire that assesses health status and health-related quality of life in participants with heart failure. KCCQ quantifies 8 domains: physical limitations, symptom stability, symptom frequency, symptom burden, total symptom (mean of symptom frequency and symptom burden), self-efficacy, quality of life and social limitations). Scores were generated for each domain and scaled from 0 (worst) to 100 (best possible status). KCCQ Total Symptoms score was calculated as mean of the following domains- symptom frequency and symptom burden and transformed to a single score which ranged from 0 (worst) -100 (best possible status), higher scores = better health status. Data for change from baseline was reported as LS mean.
Time frame: B3461028: Baseline (Day 1, pre-dose), Months 12, 30; B3461045: Months 42, 60 and 90 (time points were relative to Day 1 from B3461028; 42, 60 and 90 Months were 12, 30 and 60 Months of B3461045)
Change From Baseline in KCCQ Clinical Summary Scores at Months 12, 30 and 54: Cohort B
KCCQ: 23-item, self-administered questionnaire that assesses health status and health-related quality of life in participants with heart failure. KCCQ quantifies 8 domains: physical limitations, symptom stability, symptom frequency, symptom burden, total symptom (mean of symptom frequency and symptom burden), self-efficacy, quality of life and social limitations). Scores were generated for each domain and scaled from 0 (worst) to 100 (best possible status). KCCQ-clinical summary score was calculated as mean of the following domains- physical limitation and total symptoms and transformed to a single score which ranged from 0 (worst) -100 (best possible status), higher scores = better health status. Data for change from baseline was reported as mean.
Time frame: B3461045: Baseline (Day 1, pre-dose), Months 12, 30 and 54
Change From Baseline in KCCQ Overall Score at Months 12, 30 and 54: Cohort B
KCCQ: 23-item, self-administered questionnaire that assesses health status and health-related quality of life in participants with heart failure. KCCQ quantifies 8 domains: physical limitations, symptom stability, symptom frequency, symptom burden, total symptom (mean of symptom frequency and symptom burden), self-efficacy, quality of life and social limitations). Scores were generated for each domain and scaled from 0 (worst) to 100 (best possible status). KCCQ-overall score was calculated as mean of the following domains- physical limitation, total symptoms (average of symptom frequency \& symptom burden), quality of life, social limitation and transformed to a single score which ranged from 0 (worst) -100 (best possible status), higher scores = better health status. Data for change from baseline was reported as mean.
Time frame: B3461045: Baseline (Day 1, pre-dose), Months 12, 30 and 54
Change From Baseline in KCCQ Total Symptom Score at Months 12, 30 and 54: Cohort B
KCCQ: 23-item, self-administered questionnaire that assesses health status and health-related quality of life in participants with heart failure. KCCQ quantifies 8 domains: physical limitations, symptom stability, symptom frequency, symptom burden, total symptom (mean of symptom frequency and symptom burden), self-efficacy, quality of life and social limitations). Scores were generated for each domain and scaled from 0 (worst) to 100 (best possible status). KCCQ Total Symptoms score was calculated as mean of the following domains- symptom frequency and symptom burden and transformed to a single score which ranged from 0 (worst) -100 (best possible status), higher scores = better health status. Data for change from baseline was reported as mean.
Time frame: B3461045: Baseline (Day 1, pre-dose), Months 12, 30 and 54
Number of Participants With Shift From Baseline in New York Heart Association (NYHA) Classification at Month 6, 12, 18, 24, 30, 36, 42, 48, 54 and 60
NYHA classification: Class I: Participants with cardiovascular disease (CVD) but without resulting limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea, or anginal pain; Class II: Participants with CVD resulting in slight limitation of physical activity and were comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or angina pain; Class III: participants with CVD resulting in marked limitation of physical activity and were comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation, dyspnea, or anginal pain; Class IV: participants with CVD resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity was undertaken, discomfort was increased.
Time frame: B3461045: Baseline (Day 1, pre-dose), Months 6, 12, 18, 24, 30, 36, 42, 48, 54 and 60
Change From Baseline in Body Mass Index (BMI) at Months 6, 12, 18, 24, 30, 36, 42, 48, 54 and 60
BMI was calculated as: body weight in kilogram (kg) divided by (/) square of body height measurement in meters square (m\^2).
Time frame: B3461045: Baseline (Day 1, pre-dose), Months 6, 12, 18, 24, 30, 36, 42, 48, 54 and 60
Change From Baseline in Modified Body Mass Index (mBMI) at Months 6, 12, 18, 24, 30, 36, 42, 48, 54 and 60
Modified (m)BMI of participants was calculated to determine if there was any gastrointestinal involvement in participants. The mBMI was calculated by multiplying BMI by serum albumin concentration gram/liter (g/L).
Time frame: B3461045: Baseline (Day 1, pre-dose), Months 6, 12, 18, 24, 30, 36, 42, 48, 54 and 60
Change From Baseline in Troponin I Concentration at Months 6, 12, 18, 24, 30, 36, 42, 48, 54 and 60
Troponin I is the cardiac markers. Higher level of the marker was indicative of heart damage. It was measure in nanogram per milliliter (ng/mL). Safety analysis population included all participants (Cohorts A and B) who were enrolled in this study and taken at least 1 dose of study medication.
Time frame: B3461045: Baseline (Day 1, pre-dose), Months 6, 12, 18, 24, 30, 36, 42, 48, 54 and 60
Change From Baseline in N-Terminal Prohormone Brain Natriuretic Peptide (NT-proBNP) Concentration at Months 6, 12, 18, 24, 30, 36, 42, 48, 54 and 60
NT-proBNP was a cardiac marker which had the prognostic value for participants with heart failure or left ventricular dysfunction. It was measure in picomole per liter (pmole/L). Higher level of the marker was indicative of heart damage. Safety analysis population included all participants (Cohorts A and B) who were enrolled in this study and taken at least 1 dose of study medication.
Time frame: B3461045: Baseline (Day 1, pre-dose), Months 6, 12, 18, 24, 30, 36, 42, 48, 54 and 60
The study consisted of two cohorts: Cohort A and B. Cohort A: Participants diagnosed with transthyretin amyloid cardiomyopathy (ATTR-CM) who completed 30 months of participation in parent study \[B3461028 (NCT01994889)\] were enrolled in this current extension study (B3461045 \[NCT02791230\]). Cohort B: Participants diagnosed with ATTR-CM who did not participate in parent study B3461028 study were enrolled in this extension study.
| Milestone | Cohort A: Tafamidis (Parent and Extension Study) | Cohort A: Placebo (Parent Study)/Tafamidis (Extension Study) | Cohort B: Tafamidis (Only in Extension Study) |
|---|---|---|---|
| Started | 170 | 82 | 1481 |
| Treated | 170 | 82 | 1476 |
| Completed | 84 | 31 | 988 |
| Not completed | 86 | 51 | 493 |
| Withdrew: Adverse event | 10 | 9 | 66 |
| Withdrew: Death | 38 | 25 | 184 |
| Withdrew: Lack of efficacy | 1 | 0 | 3 |
| Withdrew: Lost to follow-up | 0 | 0 | 10 |
| Withdrew: Failure to meet randomization criteria | 3 | 2 | 15 |
| Withdrew: Medication error without associated adverse event | 0 | 1 | 1 |
| Withdrew: Study sites terminated by sponsor | 1 | 0 | 5 |
| Withdrew: Other | 9 | 1 | 28 |
| Withdrew: Protocol violation | 0 | 0 | 4 |
| Withdrew: Withdrawal by subject | 24 | 13 | 172 |
| Withdrew: Enrolled but not treated | 0 | 0 | 5 |
Time to all-cause mortality was calculated from first dose of randomized treatment in parent study (B3461028) to all-cause mortality events. All-cause mortality events included deaths, heart transplants and cardiac mechanical assist devices implantation treated as death. Treated participants from the parent study who discontinued prior to the start of this study were also included in this analysis as planned. Data from participants who dropped out for a liver-only transplantation were handled in the same manner as the data from all other censored participants. Censored participants were participants who completed study or discontinued from the study (including discontinued by sponsor or participants withdrew, or discontinued due to Adverse event (AE), or alive at the time of analysis. Kaplan Meier method was used for analysis. Therefore, this analysis was based on the pooled dose groups, as per the statistical analysis plan (SAP).
| Months | Cohort A: Tafamidis (Parent Study) and Tafamidis (Extension Study) | Cohort A: Placebo (Parent Study) and Tafamidis (Extension Study) |
|---|---|---|
| Time to All-Cause Mortality: Cohort A | 58.7 (50.3 to 68.4) | 35.8 (29.7 to 41.1) |
All-cause mortality included all participants who had discontinue for transplantation (i.e. heart transplantation and combined heart and liver transplantation) or for implantation of a cardiac mechanical assist device, were handled in the same manner as death. Data from participants who dropped out for a liver-only transplantation were handled in the same manner as the data from all other censored participants. Censored participants were participants who completed study or discontinued from the study (including discontinued by sponsor or participants withdrew, or discontinued due to AE), or alive at the time of analysis. Kaplan Meier method was used for analysis.
| Participants | Cohort B: Tafamidis (Only in Extension Study) |
|---|---|
| Number of Participants With All-Cause Mortality Events: Cohort B | 345 |
An AE was any untoward medical occurrence in a participant who received investigational product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment or worsened during the treatment period relative to the pretreatment state. AEs included both SAEs and all Non-SAEs. A serious adverse event (SAE) was any untoward medical occurrence at any dose that: resulted in death; was life-threatening (immediate risk of death); required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/ incapacity; resulted in congenital anomaly/birth defect; considered an important medical event.
| Participants | Cohort A: Tafamidis (Parent and Extension Study) | Cohort A: Placebo (Parent Study)/Tafamidis (Extension Study) | Cohort B: Tafamidis (Only in Extension Study) |
|---|---|---|---|
| Number of Participants With Treatment-Emergent Adverse Events (AEs) | 168 | 79 | 1294 |
Time to cardiovascular-related mortality was calculated from first dose of randomized treatment in B3461028 . Participants who discontinued for transplantation (that is heart transplantation and combined heart and liver transplantation) or for implantation of cardiac mechanical assist device were treated as a death. Treated participants from the parent study who discontinued prior to the start of this study were also included in this analysis as planned. Kaplan-Meier method was used. Therefore, this analysis was based on the pooled dose groups, as per the SAP.
| Months | Cohort A: Tafamidis (Parent Study) and Tafamidis (Extension Study) | Cohort A: Placebo (Parent Study) and Tafamidis (Extension Study) |
|---|---|---|
| Time to Cardiovascular-Related Mortality Events: Cohort A | 70.2 (63.4 to 88.8) | 40.8 (34.1 to 50.7) |
Deaths adjudicated as cardiovascular-related and indeterminate were reported. Cardiovascular-related mortality events included deaths, heart transplants and cardiac mechanical assist devices implantation treated as death. Cardiovascular relatedness was based on clinical judgement.
| Participants | Cohort B: Tafamidis (Only in Extension Study) |
|---|---|
| Number of Participants With Cardiovascular Related Mortality Events: Cohort B | 204 |
Mean annual rate of all cause hospitalization was calculated for each participant as the participant's number of all cause hospitalizations divided by this participant's duration on study in years. Hospitalization was defined as any initial admission (even less than 24 hours) in a hospital or equivalent healthcare facility or any prolongation of an existing admission. Only all cause hospitalizations where the participant was admitted to a hospital during the current extension study were included in this analysis. Any hospitalizations prior to randomization date were not included.
| Hospitalization/year | Cohort A: Tafamidis (Parent and Extension Study) | Cohort A: Placebo (Parent Study)/Tafamidis (Extension Study) | Cohort B: Tafamidis (Only in Extension Study) |
|---|---|---|---|
| Mean Annualized Rate of All Cause Hospitalizations | 1.67 ± 5.830 | 1.84 ± 2.275 | 0.96 ± 5.117 |
Mean annual rate of CV related hospitalization was calculated for each participant as the participant's number of CV related hospitalizations divided by this participant's duration on study in years. CV-related hospitalizations included hospitalizations due to heart failure, arrhythmia, myocardial infarction, stroke, and other cardiovascular-related events. Hospitalization was defined as any initial admission (even less than 24 hours) in a hospital or equivalent healthcare facility or any prolongation of an existing admission. Admission also included transfer within the hospital to an acute/intensive care unit (example: from the psychiatric wing to a medical floor, medical floor to a coronary care unit, or neurological floor to a tuberculosis unit).
| CV related hospitalization/year | Cohort A: Tafamidis (Parent and Extension Study) | Cohort A: Placebo (Parent Study)/Tafamidis (Extension Study) | Cohort B: Tafamidis (Only in Extension Study) |
|---|---|---|---|
| Mean Annualized Rate of Cardiovascular (CV)-Related Hospitalizations | 1.09 ± 5.409 | 1.14 ± 1.899 | 0.50 ± 1.567 |
KCCQ: 23-item, self-administered questionnaire that assesses health status and health-related quality of life in participants with heart failure. KCCQ quantifies 8 domains: physical limitations, symptom stability, symptom frequency, symptom burden, total symptom (mean of symptom frequency and symptom burden), self-efficacy, quality of life and social limitations). Scores were generated for each domain and scaled from 0 (worst) to 100 (best possible status). KCCQ-clinical summary score was calculated as mean of the following domains- physical limitation and total symptoms and transformed to a single score which ranged from 0 (worst) -100 (best possible status), higher scores = better health status. Data for change from baseline was reported as least square (LS) mean.
| Units on a scale | Cohort A: Tafamidis (Parent Study) and Tafamidis (Extension Study) | Cohort A: Placebo (Parent Study) and Tafamidis (Extension Study) |
|---|---|---|
| Change at Month 12 | -3.17 ± 1.016 | -10.2 ± 1.316 |
| Change at Month 30 | -7.41 ± 1.185 | -19.9 ± 1.999 |
| Change at Month 42 | -11.2 ± 1.483 | -25.4 ± 2.143 |
| Change at Month 60 | -11.8 ± 1.756 | -25.1 ± 3.287 |
| Change at Month 90 | -17.4 ± 2.758 | -56.9 ± 1.868 |
KCCQ: 23-item, self-administered questionnaire that assesses health status and health-related quality of life in participants with heart failure. KCCQ quantifies 8 domains: physical limitations, symptom stability, symptom frequency, symptom burden, total symptom (mean of symptom frequency and symptom burden), self-efficacy, quality of life and social limitations). Scores were generated for each domain and scaled from 0 (worst) to 100 (best possible status). KCCQ-overall score was calculated as mean of the following domains- physical limitation, total symptoms (average of symptom frequency \& symptom burden), quality of life, social limitation and transformed to a single score which ranged from 0 (worst) -100 (best possible status), higher scores = better health status. Data for change from baseline was reported as LS mean.
| Units on a scale | Cohort A: Tafamidis (Parent Study) and Tafamidis (Extension Study) | Cohort A: Placebo (Parent Study) and Tafamidis (Extension Study) |
|---|---|---|
| Change at Month 12 | -1.97 ± 1.131 | -9.69 ± 1.428 |
| Change at Month 30 | -6.07 ± 1.399 | -19.5 ± 1.908 |
| Change at Month 42 | -8.81 ± 1.470 | -24.0 ± 2.114 |
| Change at Month 60 | -8.56 ± 1.646 | -24.5 ± 3.020 |
| Change at Month 90 | -18.1 ± 2.617 | -52.6 ± 1.791 |
KCCQ: 23-item, self-administered questionnaire that assesses health status and health-related quality of life in participants with heart failure. KCCQ quantifies 8 domains: physical limitations, symptom stability, symptom frequency, symptom burden, total symptom (mean of symptom frequency and symptom burden), self-efficacy, quality of life and social limitations). Scores were generated for each domain and scaled from 0 (worst) to 100 (best possible status). KCCQ Total Symptoms score was calculated as mean of the following domains- symptom frequency and symptom burden and transformed to a single score which ranged from 0 (worst) -100 (best possible status), higher scores = better health status. Data for change from baseline was reported as LS mean.
| Units on a scale | Cohort A: Tafamidis (Parent Study) and Tafamidis (Extension Study) | Cohort A: Placebo (Parent Study) and Tafamidis (Extension Study) |
|---|---|---|
| Change at Month 12 | -2.90 ± 1.182 | -10.3 ± 1.494 |
| Change at Month 30 | -5.92 ± 1.279 | -18.7 ± 2.276 |
| Change at Month 42 | -9.29 ± 1.699 | -22.5 ± 2.237 |
| Change at Month 60 | -8.94 ± 1.858 | -19.0 ± 3.693 |
| Change at Month 90 | -16.4 ± 2.654 | -56.0 ± 1.958 |
KCCQ: 23-item, self-administered questionnaire that assesses health status and health-related quality of life in participants with heart failure. KCCQ quantifies 8 domains: physical limitations, symptom stability, symptom frequency, symptom burden, total symptom (mean of symptom frequency and symptom burden), self-efficacy, quality of life and social limitations). Scores were generated for each domain and scaled from 0 (worst) to 100 (best possible status). KCCQ-clinical summary score was calculated as mean of the following domains- physical limitation and total symptoms and transformed to a single score which ranged from 0 (worst) -100 (best possible status), higher scores = better health status. Data for change from baseline was reported as mean.
| Units on a scale | Cohort B: Tafamidis (Only in Extension Study) |
|---|---|
| Change at Month 12 | -0.242 ± 17.7032 |
| Change at Month 30 | -3.086 ± 20.4276 |
| Change at Month 54 | -3.988 ± 18.7931 |
KCCQ: 23-item, self-administered questionnaire that assesses health status and health-related quality of life in participants with heart failure. KCCQ quantifies 8 domains: physical limitations, symptom stability, symptom frequency, symptom burden, total symptom (mean of symptom frequency and symptom burden), self-efficacy, quality of life and social limitations). Scores were generated for each domain and scaled from 0 (worst) to 100 (best possible status). KCCQ-overall score was calculated as mean of the following domains- physical limitation, total symptoms (average of symptom frequency \& symptom burden), quality of life, social limitation and transformed to a single score which ranged from 0 (worst) -100 (best possible status), higher scores = better health status. Data for change from baseline was reported as mean.
| Units on a scale | Cohort B: Tafamidis (Only in Extension Study) |
|---|---|
| Change at Month 12 | 0.443 ± 18.2575 |
| Change at Month 30 | -1.378 ± 20.9437 |
| Change at Month 54 | -2.093 ± 19.5085 |
KCCQ: 23-item, self-administered questionnaire that assesses health status and health-related quality of life in participants with heart failure. KCCQ quantifies 8 domains: physical limitations, symptom stability, symptom frequency, symptom burden, total symptom (mean of symptom frequency and symptom burden), self-efficacy, quality of life and social limitations). Scores were generated for each domain and scaled from 0 (worst) to 100 (best possible status). KCCQ Total Symptoms score was calculated as mean of the following domains- symptom frequency and symptom burden and transformed to a single score which ranged from 0 (worst) -100 (best possible status), higher scores = better health status. Data for change from baseline was reported as mean.
| Units on a scale | Cohort B: Tafamidis (Only in Extension Study) |
|---|---|
| Change at Month 12 | 0.738 ± 19.1549 |
| Change at Month 30 | -1.112 ± 20.7952 |
| Change at Month 54 | -1.885 ± 19.4433 |
NYHA classification: Class I: Participants with cardiovascular disease (CVD) but without resulting limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea, or anginal pain; Class II: Participants with CVD resulting in slight limitation of physical activity and were comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or angina pain; Class III: participants with CVD resulting in marked limitation of physical activity and were comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation, dyspnea, or anginal pain; Class IV: participants with CVD resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity was undertaken, discomfort was increased.
| Participants | Cohort A: Tafamidis (Parent and Extension Study) | Cohort A: Placebo (Parent Study)/Tafamidis (Extension Study) | Cohort B: Tafamidis (Only in Extension Study) |
|---|---|---|---|
| Month 6 — Class I (Baseline) to Class I | 13 | 4 | 132 |
| Month 6 — Class I (Baseline) to Class II | 4 | 2 | 70 |
| Month 6 — Class I (Baseline) to Class III | 0 | 0 | 8 |
| Month 6 — Class I (Baseline) to Class IV | 0 | 0 | 0 |
| Month 6 — Class II (Baseline) to Class I | 7 | 0 | 60 |
| Month 6 — Class II (Baseline) to Class II | 65 | 20 | 542 |
| Month 6 — Class II (Baseline) to Class III | 11 | 2 | 100 |
| Month 6 — Class II (Baseline) to Class IV | 0 | 0 | 1 |
| Month 6 — Class III (Baseline) to Class I | 1 | 0 | 4 |
| Month 6 — Class III (Baseline) to Class II | 17 | 9 | 88 |
| Month 6 — Class III (Baseline) to Class III | 34 | 24 | 226 |
| Month 6 — Class III (Baseline) to Class IV | 0 | 0 | 2 |
| Month 6 — Class IV (Baseline) to Class I | 0 | 0 | 1 |
| Month 6 — Class IV (Baseline) to Class II | 1 | 1 | 2 |
| Month 6 — Class IV (Baseline) to Class III | 1 | 3 | 10 |
| Month 6 — Class IV (Baseline) to Class IV | 1 | 1 | 3 |
| Month 12 — Class I (Baseline) to Class I | 10 | 4 | 94 |
| Month 12 — Class I (Baseline) to Class II | 5 | 0 | 60 |
| Month 12 — Class I (Baseline) to Class III | 1 | 0 | 3 |
| Month 12 — Class I (Baseline) to Class IV | 0 | 0 | 0 |
| Month 12 — Class II (Baseline) to Class I | 6 | 0 | 50 |
| Month 12 — Class II (Baseline) to Class II | 63 | 16 | 371 |
| Month 12 — Class II (Baseline) to Class III | 10 | 1 | 67 |
| Month 12 — Class II (Baseline) to Class IV | 1 | 0 | 1 |
| Month 12 — Class III (Baseline) to Class I | 3 | 0 | 1 |
| Month 12 — Class III (Baseline) to Class II | 12 | 9 | 67 |
| Month 12 — Class III (Baseline) to Class III | 31 | 23 | 127 |
| Month 12 — Class III (Baseline) to Class IV | 0 | 0 | 0 |
| Month 12 — Class IV (Baseline) to Class I | 0 | 0 | 0 |
| Month 12 — Class IV (Baseline) to Class II | 0 | 0 | 1 |
| Month 12 — Class IV (Baseline) to Class III | 0 | 1 | 7 |
| Month 12 — Class IV (Baseline) to Class IV | 0 | 0 | 1 |
| Month 18 — Class I (Baseline) to Class I | 5 | 4 | 64 |
| Month 18 — Class I (Baseline) to Class II | 3 | 0 | 45 |
| Month 18 — Class I (Baseline) to Class III | 0 | 0 | 3 |
| Month 18 — Class I (Baseline) to Class IV | 0 | 0 | 0 |
| Month 18 — Class II (Baseline) to Class I | 8 | 0 | 41 |
| Month 18 — Class II (Baseline) to Class II | 49 | 15 | 259 |
| Month 18 — Class II (Baseline) to Class III | 9 | 1 | 61 |
| Month 18 — Class II (Baseline) to Class IV | 0 | 0 | 1 |
| Month 18 — Class III (Baseline) to Class I | 2 | 0 | 5 |
| Month 18 — Class III (Baseline) to Class II | 19 | 6 | 57 |
| Month 18 — Class III (Baseline) to Class III | 24 | 19 | 70 |
| Month 18 — Class III (Baseline) to Class IV | 0 | 0 | 0 |
| Month 18 — Class IV (Baseline) to Class I | 2 | 0 | 0 |
| Month 18 — Class IV (Baseline) to Class II | 0 | 0 | 2 |
| Month 18 — Class IV (Baseline) to Class III | 2 | 2 | 3 |
| Month 18 — Class IV (Baseline) to Class IV | 0 | 0 | 0 |
| Month 24 — Class I (Baseline) to Class I | 4 | 4 | 42 |
| Month 24 — Class I (Baseline) to Class II | 4 | 1 | 40 |
| Month 24 — Class I (Baseline) to Class III | 2 | 1 | 0 |
| Month 24 — Class I (Baseline) to Class IV | 0 | 0 | 0 |
| Month 24 — Class II (Baseline) to Class I | 8 | 0 | 31 |
| Month 24 — Class II (Baseline) to Class II | 49 | 12 | 191 |
| Month 24 — Class II (Baseline) to Class III | 3 | 0 | 42 |
| Month 24 — Class II (Baseline) to Class IV | 0 | 0 | 0 |
| Month 24 — Class III (Baseline) to Class I | 4 | 0 | 3 |
| Month 24 — Class III (Baseline) to Class II | 11 | 8 | 34 |
| Month 24 — Class III (Baseline) to Class III | 17 | 14 | 46 |
| Month 24 — Class III (Baseline) to Class IV | 0 | 0 | 0 |
| Month 24 — Class IV (Baseline) to Class I | 0 | 0 | 0 |
| Month 24 — Class IV (Baseline) to Class II | 1 | 0 | 1 |
| Month 24 — Class IV (Baseline) to Class III | 2 | 0 | 4 |
| Month 24 — Class IV (Baseline) to Class IV | 0 | 0 | 0 |
| Month 30 — Class I (Baseline) to Class I | 1 | 1 | 27 |
| Month 30 — Class I (Baseline) to Class II | 1 | 0 | 32 |
| Month 30 — Class I (Baseline) to Class III | 0 | 0 | 1 |
| Month 30 — Class I (Baseline) to Class IV | 0 | 0 | 0 |
| Month 30 — Class II (Baseline) to Class I | 5 | 1 | 26 |
| Month 30 — Class II (Baseline) to Class II | 27 | 7 | 129 |
| Month 30 — Class II (Baseline) to Class III | 2 | 1 | 24 |
| Month 30 — Class II (Baseline) to Class IV | 0 | 0 | 0 |
| Month 30 — Class III (Baseline) to Class I | 4 | 0 | 2 |
| Month 30 — Class III (Baseline) to Class II | 14 | 4 | 22 |
| Month 30 — Class III (Baseline) to Class III | 10 | 9 | 24 |
| Month 30 — Class III (Baseline) to Class IV | 0 | 0 | 0 |
| Month 30 — Class IV (Baseline) to Class I | 0 | 0 | 0 |
| Month 30 — Class IV (Baseline) to Class II | 0 | 0 | 2 |
| Month 30 — Class IV (Baseline) to Class III | 0 | 0 | 2 |
| Month 30 — Class IV (Baseline) to Class IV | 0 | 0 | 0 |
| Month 36 — Class I (Baseline) to Class I | 1 | 2 | 21 |
| Month 36 — Class I (Baseline) to Class II | 4 | 0 | 18 |
| Month 36 — Class I (Baseline) to Class III | 0 | 0 | 0 |
| Month 36 — Class I (Baseline) to Class IV | 0 | 0 | 0 |
| Month 36 — Class II (Baseline) to Class I | 3 | 0 | 19 |
| Month 36 — Class II (Baseline) to Class II | 19 | 7 | 101 |
| Month 36 — Class II (Baseline) to Class III | 2 | 1 | 25 |
| Month 36 — Class II (Baseline) to Class IV | 0 | 0 | 0 |
| Month 36 — Class III (Baseline) to Class I | 1 | 0 | 3 |
| Month 36 — Class III (Baseline) to Class II | 5 | 2 | 21 |
| Month 36 — Class III (Baseline) to Class III | 7 | 4 | 14 |
| Month 36 — Class III (Baseline) to Class IV | 0 | 0 | 0 |
| Month 36 — Class IV (Baseline) to Class I | 0 | 0 | 0 |
| Month 36 — Class IV (Baseline) to Class II | 1 | 0 | 1 |
| Month 36 — Class IV (Baseline) to Class III | 0 | 1 | 0 |
| Month 36 — Class IV (Baseline) to Class IV | 0 | 0 | 0 |
| Month 42 — Class I (Baseline) to Class I | 0 | 0 | 16 |
| Month 42 — Class I (Baseline) to Class II | 3 | 1 | 11 |
| Month 42 — Class I (Baseline) to Class III | 0 | 0 | 1 |
| Month 42 — Class I (Baseline) to Class IV | 0 | 0 | 0 |
| Month 42 — Class II (Baseline) to Class I | 4 | 1 | 9 |
| Month 42 — Class II (Baseline) to Class II | 14 | 4 | 77 |
| Month 42 — Class II (Baseline) to Class III | 2 | 0 | 16 |
| Month 42 — Class II (Baseline) to Class IV | 0 | 0 | 0 |
| Month 42 — Class III (Baseline) to Class I | 1 | 0 | 1 |
| Month 42 — Class III (Baseline) to Class II | 3 | 1 | 20 |
| Month 42 — Class III (Baseline) to Class III | 4 | 1 | 12 |
| Month 42 — Class III (Baseline) to Class IV | 0 | 0 | 0 |
| Month 42 — Class IV (Baseline) to Class I | 0 | 0 | 0 |
| Month 42 — Class IV (Baseline) to Class II | 0 | 0 | 0 |
| Month 42 — Class IV (Baseline) to Class III | 0 | 0 | 0 |
| Month 42 — Class IV (Baseline) to Class IV | 0 | 0 | 0 |
| Month 48 — Class I (Baseline) to Class I | 0 | 0 | 6 |
| Month 48 — Class I (Baseline) to Class II | 2 | 0 | 8 |
| Month 48 — Class I (Baseline) to Class III | 0 | 0 | 0 |
| Month 48 — Class I (Baseline) to Class IV | 0 | 0 | 0 |
| Month 48 — Class II (Baseline) to Class I | 2 | 1 | 2 |
| Month 48 — Class II (Baseline) to Class II | 12 | 4 | 54 |
| Month 48 — Class II (Baseline) to Class III | 2 | 0 | 7 |
| Month 48 — Class II (Baseline) to Class IV | 0 | 0 | 0 |
| Month 48 — Class III (Baseline) to Class I | 2 | 0 | 0 |
| Month 48 — Class III (Baseline) to Class II | 3 | 1 | 8 |
| Month 48 — Class III (Baseline) to Class III | 4 | 1 | 13 |
| Month 48 — Class III (Baseline) to Class IV | 0 | 0 | 0 |
| Month 48 — Class IV (Baseline) to Class I | 0 | 0 | 0 |
| Month 48 — Class IV (Baseline) to Class II | 0 | 0 | 0 |
| Month 48 — Class IV (Baseline) to Class III | 0 | 0 | 1 |
| Month 48 — Class IV (Baseline) to Class IV | 0 | 0 | 0 |
| Month 54 — Class I (Baseline) to Class I | 0 | 0 | 1 |
| Month 54 — Class I (Baseline) to Class II | 0 | 0 | 3 |
| Month 54 — Class I (Baseline) to Class III | 0 | 0 | 0 |
| Month 54 — Class I (Baseline) to Class IV | 0 | 0 | 0 |
| Month 54 — Class II (Baseline) to Class I | 0 | 0 | 1 |
| Month 54 — Class II (Baseline) to Class II | 7 | 3 | 22 |
| Month 54 — Class II (Baseline) to Class III | 2 | 0 | 6 |
| Month 54 — Class II (Baseline) to Class IV | 0 | 0 | 0 |
| Month 54 — Class III (Baseline) to Class I | 3 | 0 | 0 |
| Month 54 — Class III (Baseline) to Class II | 3 | 1 | 4 |
| Month 54 — Class III (Baseline) to Class III | 3 | 0 | 7 |
| Month 54 — Class III (Baseline) to Class IV | 0 | 0 | 0 |
| Month 54 — Class IV (Baseline) to Class I | 0 | 0 | 0 |
| Month 54 — Class IV (Baseline) to Class II | 0 | 0 | 0 |
| Month 54 — Class IV (Baseline) to Class III | 0 | 0 | 0 |
| Month 54 — Class IV (Baseline) to Class IV | 0 | 0 | 0 |
| Month 60 — Class I (Baseline) to Class I | 0 | 0 | — |
| Month 60 — Class I (Baseline) to Class II | 0 | 0 | — |
| Month 60 — Class I (Baseline) to Class III | 0 | 0 | — |
| Month 60 — Class I (Baseline) to Class IV | 0 | 0 | — |
| Month 60 — Class II (Baseline) to Class I | 0 | 0 | — |
| Month 60 — Class II (Baseline) to Class II | 4 | 0 | — |
| Month 60 — Class II (Baseline) to Class III | 2 | 0 | — |
| Month 60 — Class II (Baseline) to Class IV | 0 | 0 | — |
| Month 60 — Class III (Baseline) to Class I | 1 | 0 | — |
| Month 60 — Class III (Baseline) to Class II | 1 | 2 | — |
| Month 60 — Class III (Baseline) to Class III | 1 | 0 | — |
| Month 60 — Class III (Baseline) to Class IV | 0 | 0 | — |
| Month 60 — Class IV (Baseline) to Class I | 0 | 0 | — |
| Month 60 — Class IV (Baseline) to Class II | 0 | 0 | — |
| Month 60 — Class IV (Baseline) to Class III | 0 | 0 | — |
| Month 60 — Class IV (Baseline) to Class IV | 0 | 0 | — |
BMI was calculated as: body weight in kilogram (kg) divided by (/) square of body height measurement in meters square (m\^2).
| kg/m^2 | Cohort A: Tafamidis (Parent and Extension Study) | Cohort A: Placebo (Parent Study)/Tafamidis (Extension Study) | Cohort B: Tafamidis (Only in Extension Study) |
|---|---|---|---|
| Change at Month 6 | -0.07 ± 0.873 | -0.27 ± 0.900 | -0.24 ± 1.234 |
| Change at Month 12 | -0.21 ± 1.212 | -0.40 ± 1.440 | -0.20 ± 1.552 |
| Change at Month 18 | -0.38 ± 1.442 | -0.85 ± 1.502 | -0.30 ± 1.956 |
| Change at Month 24 | -0.36 ± 1.407 | -0.78 ± 1.668 | -0.43 ± 1.747 |
| Change at Month 30 | -0.71 ± 1.423 | -1.28 ± 1.814 | -0.41 ± 1.802 |
| Change at Month 36 | -1.18 ± 2.200 | -0.49 ± 1.852 | -0.69 ± 1.730 |
| Change at Month 42 | -0.91 ± 1.402 | -0.11 ± 1.523 | -0.74 ± 1.827 |
| Change at Month 48 | -1.14 ± 1.480 | -0.01 ± 1.927 | -0.83 ± 1.732 |
| Change at Month 54 | -1.03 ± 1.716 | -1.54 ± 0.528 | -1.24 ± 1.942 |
| Change at Month 60 | -0.93 ± 2.102 | -1.62 ± 0.834 | — |
Modified (m)BMI of participants was calculated to determine if there was any gastrointestinal involvement in participants. The mBMI was calculated by multiplying BMI by serum albumin concentration gram/liter (g/L).
| (kg/m^2) *(g/L) | Cohort A: Tafamidis (Parent and Extension Study) | Cohort A: Placebo (Parent Study)/Tafamidis (Extension Study) | Cohort B: Tafamidis (Only in Extension Study) |
|---|---|---|---|
| Change at Month 6 | -2.96 ± 36.046 | -10.91 ± 36.338 | -8.51 ± 51.329 |
| Change at Month 12 | -7.42 ± 49.840 | -16.09 ± 57.882 | -6.17 ± 66.094 |
| Change at Month 18 | -15.46 ± 60.361 | -35.46 ± 63.390 | -10.08 ± 85.605 |
| Change at Month 24 | -15.07 ± 58.706 | -32.33 ± 71.104 | -15.81 ± 74.009 |
| Change at Month 30 | -29.31 ± 61.003 | -52.81 ± 78.705 | -15.70 ± 79.724 |
| Change at Month 36 | -49.46 ± 98.257 | -17.81 ± 80.327 | -24.66 ± 74.366 |
| Change at Month 42 | -36.32 ± 58.130 | 1.59 ± 69.701 | -28.06 ± 78.987 |
| Change at Month 48 | -46.43 ± 62.394 | 14.05 ± 83.969 | -32.91 ± 71.745 |
| Change at Month 54 | -41.98 ± 74.883 | -52.80 ± 14.562 | -51.15 ± 79.618 |
| Change at Month 60 | -38.90 ± 92.253 | -41.20 ± NA | — |
Troponin I is the cardiac markers. Higher level of the marker was indicative of heart damage. It was measure in nanogram per milliliter (ng/mL). Safety analysis population included all participants (Cohorts A and B) who were enrolled in this study and taken at least 1 dose of study medication.
| ng/mL | Cohort A: Tafamidis (Parent and Extension Study) | Cohort A: Placebo (Parent Study)/Tafamidis (Extension Study) | Cohort B: Tafamidis (Only in Extension Study) |
|---|---|---|---|
| Change at Month 6 | — | — | 0.012 ± 0.1706 |
| Change at Month 12 | 0.035 ± 0.3977 | 0.037 ± 0.0853 | 0.009 ± 0.0893 |
| Change at Month 18 | 0.040 ± NA | — | -0.007 ± 0.0786 |
| Change at Month 24 | 0.000 ± 0.0566 | 0.033 ± 0.0306 | -0.031 ± 0.2031 |
| Change at Month 30 | 0.022 ± 0.1599 | 0.100 ± 0.1728 | -0.033 ± 0.2055 |
| Change at Month 36 | 0.009 ± 0.0579 | 0.018 ± 0.1057 | -0.034 ± 0.1913 |
| Change at Month 42 | -0.002 ± 0.0795 | -0.047 ± 0.0755 | -0.021 ± 0.2484 |
| Change at Month 48 | 0.016 ± 0.0795 | -0.067 ± 0.2040 | -0.100 ± 0.0000 |
| Change at Month 54 | -0.033 ± 0.0792 | -0.363 ± 0.6080 | — |
| Change at Month 60 | -0.040 ± 0.0414 | 0.035 ± 0.0354 | — |
NT-proBNP was a cardiac marker which had the prognostic value for participants with heart failure or left ventricular dysfunction. It was measure in picomole per liter (pmole/L). Higher level of the marker was indicative of heart damage. Safety analysis population included all participants (Cohorts A and B) who were enrolled in this study and taken at least 1 dose of study medication.
| pmole/L | Cohort A: Tafamidis (Parent and Extension Study) | Cohort A: Placebo (Parent Study)/Tafamidis (Extension Study) | Cohort B: Tafamidis (Only in Extension Study) |
|---|---|---|---|
| Change at Month 6 | — | — | 24.820 ± 171.2075 |
| Change at Month 12 | 31.117 ± 220.9279 | 127.973 ± 226.7727 | 32.686 ± 180.4921 |
| Change at Month 18 | 226.442 ± NA | — | 71.582 ± 329.5411 |
| Change at Month 24 | 131.334 ± 119.5258 | 256.442 ± 101.8073 | 92.899 ± 320.6054 |
| Change at Month 30 | 159.596 ± 404.8483 | 417.682 ± 597.9224 | 149.049 ± 320.8814 |
| Change at Month 36 | 322.963 ± 215.1605 | 420.196 ± 251.8446 | 88.895 ± 227.7375 |
| Change at Month 42 | 419.034 ± 315.6436 | 324.211 ± 173.6652 | 191.318 ± 482.3582 |
| Change at Month 48 | 492.154 ± 387.4700 | 400.571 ± 228.4343 | 264.566 ± 78.7059 |
| Change at Month 54 | 405.887 ± 457.6349 | 340.082 ± 190.6412 | — |
| Change at Month 60 | 392.363 ± 271.2883 | 314.184 ± 274.6756 | — |
Collected over B3461045: From first dose of treatment up to 28 days post last dose of study treatment (approximately up to 61 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort A: Tafamidis (Parent and Extension Study) | 45/170 (26.5%) | 132/170 (77.6%) | 152/170 (89.4%) |
| Cohort A: Placebo (Parent Study)/Tafamidis (Extension Study) | 33/82 (40.2%) | 64/82 (78%) | 76/82 (92.7%) |
| Cohort B: Tafamidis (Only in Extension Study) | 203/1,476 (13.8%) | 736/1,476 (49.9%) | 1,023/1,476 (69.3%) |
| Event | Cohort A: Tafamidis (Parent and Extension Study) | Cohort A: Placebo (Parent Study)/Tafamidis (Extension Study) | Cohort B: Tafamidis (Only in Extension Study) |
|---|---|---|---|
| Cardiac failureCardiac disorders | 30/170 | 17/82 | 169/1476 |
| Cardiac failure congestiveCardiac disorders | 17/170 | 14/82 | 52/1476 |
| Acute kidney injuryRenal and urinary disorders | 16/170 | 13/82 | 34/1476 |
| Cardiac failure acuteCardiac disorders | 13/170 | 10/82 | 48/1476 |
| PneumoniaInfections and infestations | 12/170 | 9/82 | 39/1476 |
| Atrial fibrillationCardiac disorders | 11/170 | 8/82 | 62/1476 |
| Ventricular tachycardiaCardiac disorders | 3/170 | 6/82 | 17/1476 |
| CellulitisInfections and infestations | 8/170 | 5/82 | 18/1476 |
| FallInjury, poisoning and procedural complications | 10/170 | 5/82 | 25/1476 |
| DehydrationMetabolism and nutrition disorders | 0/170 | 5/82 | 7/1476 |
| Event | Cohort A: Tafamidis (Parent and Extension Study) | Cohort A: Placebo (Parent Study)/Tafamidis (Extension Study) | Cohort B: Tafamidis (Only in Extension Study) |
|---|---|---|---|
| FallInjury, poisoning and procedural complications | 41/170 | 34/82 | 146/1476 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 23/170 | 24/82 | 58/1476 |
| HypotensionVascular disorders | 14/170 | 20/82 | 70/1476 |
| Oedema peripheralGeneral disorders | 26/170 | 18/82 | 100/1476 |
| CoughRespiratory, thoracic and mediastinal disorders | 29/170 | 18/82 | 81/1476 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 31/170 | 18/82 | 110/1476 |
| Atrial fibrillationCardiac disorders | 32/170 | 17/82 | 150/1476 |
| HypokalaemiaMetabolism and nutrition disorders | 23/170 | 17/82 | 61/1476 |
| Urinary tract infectionInfections and infestations | 18/170 | 16/82 | 75/1476 |
| ConstipationGastrointestinal disorders | 18/170 | 15/82 | 117/1476 |
The safety analysis population consisted of all participants (Cohorts A and B) who were enrolled in this study and who had taken at least one dose of study treatment.
| Age, Continuous(Years) | Cohort A: Tafamidis (Parent and Extension Study) | Cohort A: Placebo (Parent Study)/Tafamidis (Extension Study) | Cohort B: Tafamidis (Only in Extension Study) | Total |
|---|---|---|---|---|
| Mean | 76.73 ± 6.75 | 76.41 ± 6.47 | 76.51 ± 7.75 | 76.52 ± 7.60 |
| Sex: Female, Male(Participants) | Cohort A: Tafamidis (Parent and Extension Study) | Cohort A: Placebo (Parent Study)/Tafamidis (Extension Study) | Cohort B: Tafamidis (Only in Extension Study) | Total |
|---|---|---|---|---|
| Female | 13 | 8 | 165 | 186 |
| Male | 157 | 74 | 1311 | 1542 |
| Ethnicity (NIH/OMB)(Participants) | Cohort A: Tafamidis (Parent and Extension Study) | Cohort A: Placebo (Parent Study)/Tafamidis (Extension Study) | Cohort B: Tafamidis (Only in Extension Study) | Total |
|---|---|---|---|---|
| Hispanic or Latino | 5 | 1 | 37 | 43 |
| Not Hispanic or Latino | 164 | 81 | 1433 | 1678 |
| Unknown or Not Reported | 1 | 0 | 6 | 7 |
| Race (NIH/OMB)(Participants) | Cohort A: Tafamidis (Parent and Extension Study) | Cohort A: Placebo (Parent Study)/Tafamidis (Extension Study) | Cohort B: Tafamidis (Only in Extension Study) | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 9 | 5 | 66 | 80 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 15 | 5 | 139 | 159 |
| White | 144 | 72 | 1252 | 1468 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 0 | 19 | 21 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Jun 2016 to primary completion in Oct 2023, 88 months.
Results were first posted in Feb 2025, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tafamidis
Amyloid Neuropathies, Familial →